Answers are grounded in this paper and cite their sources.
We recommend more substantial dose reductions to individualize MP therapy and mitigate toxicity in TPMT/NUDT15 IM/IM patients.
No takes yet. Share an insight, caveat, or question.
Maillard et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: